A new educational resource for diabetes is now available on the Internet, thanks to the UCSF Diabetes Teaching Center (DTC). Since it was launched in July 2008, thousands of families have visited the site. DTC Medical Director Martha Nolte Kennedy, MD and her staff are pleased that this website is providing diabetes education and self-management skills to the growing numbers worldwide who have limited access to diabetes specialists.
Last month, Doug Hanahan, PhD was elected to the prestigious Institute of Medicine (IOM), an organization that serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the IOM provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. Dr. Hanahan is a member of both the UCSF Diabetes Center and the Helen Diller Family Comprehensive Cancer Center.
Jeff Bluestone PhD, Mike German MD, and Matthias Hebrok PhD were recently awarded a three year JDRF Network Grant to explore Human Embryonic Stem Cell Source for Beta Cell Replacement.
Each year, the Haile T. Debas Academy of Medical Educators recognizes outstanding teachers at UCSF. These peer-nominated awards are intended to highlight outstanding front-line teachers of medical students and residents -- who might otherwise go unrecognized. We congratulate Mark Anderson, MD, PhD who was presented a 2008 Excellence in Teaching Award.
Hélène Bour-Jordan, Ph.D. and Mark S. Anderson, M.D., Ph.D.—researchers at the University of California-San Francisco (UCSF) Diabetes Center—were recently awarded a scientific research grant by The Neuropathy Association, a national patient-based non-profit organization headquartered in New York City.
A complete online diabetes education program, www.deo.ucsf.edu, has been launched by the University of California, San Francisco (UCSF) Diabetes Teaching Center. This website mirrors the highly successful American Diabetes Association (ADA) accredited teaching program curriculum created by UCSF clinicians and presented to thousands of patients at UCSF over the past 30 years.
Dr. Jeffrey A. Bluestone, University of California in San Francisco and Dr. Mark E. Cooper, Baker IDI Heart and Diabetes Institute in Melbourne, Australia, to Receive Honors & Additional Research Funding.
Beginning this year, the California Institute of Regenerative Medicine (CIRM) plans to support multi-year Disease Team Grants. To encourage planning for these awards, CIRM has created Disease Team Planning Awards that will enable a Principal Investigator to recruit a team and enlist its members to develop the content, management and administration of the proposed disease team.
Previous research has defined diabetes distress as a condition where patients become stressed about being able to manage their disease, obtaining the support they need, managing the emotional burden of diabetes, and accessing needed care.
Mark Anderson, MD, PhD and his lab at UCSF have been examining the genetic control of autoimmune diseases to better understand how the body recognizes self from non-self – and why the body attacks its own insulin-producing beta cells in type 1 diabetes. It appears that a key element to autoimmunity is AIRE, a gene that is critical to helping immune cells learn how to recognize and avoid destroying its own cells.
As a world leader in the field of organ transplantation, UCSF will celebrate its 45th year of transplantation with a week of exciting workshops, lectures and forums open to the public. UCSF Transplant Week is scheduled for September 22-28 and will feature a special presentation on “Diabetes and Islet Transplantation” to be held on Wednesday, September 24, 5-7 pm, at the Westin St. Francis Hotel.
In the United States, Western Europe and developing countries, type 2 diabetes is reaching epidemic proportions. It is now understood that the disease is part of a larger complex of disorders termed the "metabolic syndrome" -- insulin resistance, high blood pressure, cholesterol/lipid disorders, and type 2 diabetes -- that often leads to cardiovascular disease. Even with the availability of new classes of medicines, treatment of type 2 diabetes is difficult.
Earlier this year, San Diego biotech Novocell announced their success in converting human embryonic stem cells into insulin-producing beta cells, stopping type 1 diabetes in immune compromised mice. Even though the company is still a few years off from human clinical trials, the discovery rocked the diabetes world.